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Background: The organic cation transporter OCT1 (SLC22A1) mediates the uptake of vitamin B1, cationic drugs, and
xenobiotics into hepatocytes. Nine percent of Caucasians lack or have very low OCT1 activity due to loss-of-function
polymorphisms in OCT1 gene. Here we analyzed the global genetic variability in OCT1 to estimate the therapeutic
relevance of OCT1 polymorphisms in populations beyond Caucasians and to identify evolutionary patterns of the
common loss of OCT1 activity in humans.
Methods: We applied massively parallel sequencing to screen for coding polymorphisms in 1,079 unrelated
individuals from 53 populations worldwide. The obtained data was combined with the existing 1000
Genomes data comprising an additional 1,092 individuals from 14 populations. The identified OCT1 variants
were characterized in vitro regarding their cellular localization and their ability to transport 10 known OCT1
substrates. Both the population genetics data and transport data were used in tandem to generate a world
map of loss of OCT1 activity.
Results: We identified 16 amino acid substitutions potentially causing loss of OCT1 function and analyzed
them together with five amino acid substitutions that were not expected to affect OCT1 function. The variants
constituted 16 major alleles and 14 sub-alleles. Six major alleles showed improper subcellular localization leading to
substrate-wide loss in activity. Five major alleles showed correct subcellular localization, but substrate-specific loss of
activity. Striking differences were observed in the frequency of loss of OCT1 activity worldwide. While most East Asian
and Oceanian individuals had completely functional OCT1, 80 % of native South American Indians lacked functional
OCT1 alleles. In East Asia and Oceania the average nucleotide diversity of the loss-of-function variants was much
lower than that of the variants that do not affect OCT1 function (ratio of 0.03) and was significantly lower than the
theoretically expected heterozygosity (Tajima’s D = −1.64, P < 0.01).
Conclusions: Comprehensive genetic analyses showed strong global variations in the frequency of loss of OCT1
activity with selection pressure for maintaining OCT1 activity in East Asia and Oceania. These results not only enable
pharmacogenetically-based optimization of drug treatment worldwide, but may help elucidate the functional role of
human OCT1.* Correspondence: mtzvetk@gwdg.de
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The polyspecific organic cation transporter OCT1
(SLC22A1) is strongly expressed in human hepato-
cytes and facilitates uptake of organic cations from
the sinusoidal blood. Known substrates of OCT1 are
vitamin B1, toxins like 1-methyl-4-phenylpyridinium
(MPP+) and monocrotaline, and clinically relevant drugs
like metformin, morphine, tropisetron, tramadol, and
others [1–9].
The human OCT1 gene is highly polymorphic. Forty
percent of Caucasians carry one and a further 9 % carry
two of the following loss-of-function polymorphisms:
arginine61-to-cysteine (Arg61Cys), cysteine88-to-arginine
(Cys88Arg), glycine401-to-serine (Gly401Ser), glycine465-
to-arginine (Gly465Arg), or a deletion of methinone420
(Met420del) [4, 10, 11]. Depending on the substrate and
zygosity, these individuals completely lack or have sub-
stantially reduced OCT1 activity [2–5]. Significant changes
in pharmacokinetics and, as a consequence, in clinical
effects of several drugs were observed in the carriers of
loss-of-function OCT1 polymorphisms [3–5, 12].
The reasons for the frequent loss of OCT1 activity
remain elusive. Although a number of endogenous mole-
cules, and recently vitamin B1, have been found to be
substrates of OCT1 [1, 13], no major differences in the
vitality or fertility were observed between the wild-type
and Oct1 knockout mice [14]. However, the liver con-
centrations of the model substrate tetraethylammonium
and the drug metformin were significantly reduced in
Oct1 knockout mice [14, 15], suggesting an important
role of OCT1 in the hepatic uptake of drugs and xenobi-
otics with cationic or weak basic structure. Recently,
reduced hepatic uptake of vitamin B1 in Oct1 knockout
mice was reported to lead to a decreased risk of hepatic
steatosis [1]. This decreased risk may improve fitness
and provide a survival advantage, although long-term
studies in mice and studies in humans to support this
are still missing.
Several studies analyzed the genetic variability in
OCT1 in detail. Kerb et al. resequenced OCT1 coding
and promoter regions in 57 Caucasians and analyzed the
polymorphisms they identified in another 190 unrelated
Caucasians [10]. They found eight non-synonymous
polymorphisms, three of which affected OCT1 activity.
Leabman et al. screened for coding genetic variants in
OCT1 and 23 other membrane transporters in 247 unre-
lated individuals: 100 European Americans, 100 African
Americans, 30 Asians, 10 Mexicans, and seven Pacific
Islanders [16]. Five out of the 15 non-synonymous vari-
ants identified by Leabman et al. were shown to strongly
decrease OCT1 activity, and three of them completely
abolished activity [11]. With a non-synonymous nu-
cleotide diversity of 5.11 × 10−4 and a ratio of non-
synonymous to synonymous nucleotide diversity of 0.46,OCT1 had the strongest genetic variability among the
organic cation transporters of the SLC22 family [16]. Sev-
eral studies analyzed the genetic variability of OCT1 in
Asians. A total of 230 Japanese individuals were rese-
quenced [17–19] and the identified non-synonymous
variants were functionally characterized [17, 20, 21]. The
number and the frequency of polymorphisms causing
loss of or decreased OCT1 function was much lower in
Asians than in Caucasians [17], suggesting the presence
of substantial inter-ethnic variability in genetically deter-
mined loss of OCT1 activity.
In this study we performed a global-scale population
genetics analysis and detailed functional analyses in
order to generate a world map of genetically determined
loss of OCT1 activity. This map should help to elucidate
the potential role of OCT1 polymorphisms in interethnic
differences in drug therapy. Furthermore, we were look-
ing for global patterns that may point to factors causing
selection pressure for the frequent loss of OCT1 activity.
This study expanded the number of individuals and
world regions analyzed far beyond the scope of previ-
ously published analyses of genetic variability in OCT1.
Here we analyzed data from 2,171 unrelated individuals
from 67 worldwide populations. Using massively parallel
sequencing we screened the OCT1 gene for amino acid
substitutions and characterized them for their effects on




One-thousand and seventy-nine DNA samples from 53
populations worldwide were analyzed in this study: 962
samples from 52 populations worldwide were obtained
from the Centre d’Etude du Polymorphisme and belong
to the Human Genome Diversity Panel (HGDP-CEPH)
[22]. The HGDP-CEPH panel was enriched with 117
DNA samples from healthy Caucasians from Germany
[23]. The human DNA samples used in this study were
completely anonymized except for geographical region
of origin. The collection of the blood specimens that
served as sources of DNA was performed in accordance
to the Declaration of Helsinki under conditions of
informed consent and with institutional review board
approvals as described in details elsewhere [22, 23].
In all the key analyses the data obtained from the
1,079 DNA samples was enriched with data from 1,092
samples from the 1000 Genome Project [24]. There was
no overlap in the samples between the HGDP-CEPH
and 1000 Genome panels. The analyses of the amino
acid substitution frequencies, haplotype inferences, ana-
lyses of haplotype frequencies, the global analyses of loss
of OCT1 activity, and the calculation of the population
genetic parameters were performed using the combined
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the 14 populations within the 1000 Genomes project repre-
sent admixed populations and/or population of unknown
geographic origin (the populations CLM, MXL, PUR, CEU,
and ASW; Table 1). These populations were not used in
the global analyses of loss of OCT1 activity and in the cal-
culations of the population genetic parameters.Massively parallel re-sequencing
Eleven regions covering the eleven OCT1 exons and their
flanking regions were resequenced using semiconductor-
based massively parallel sequencing (Ion TorrentTM, Life
Technologies, Darmstadt, Germany). The newly identified,
potentially loss-of-function amino acid substitutions were
validated by capillary sequencing. Conventional geno-
typing techniques were used to call individual geno-
types of 21 amino acid substitutions. The genotypes
of 16 genetic variants (Ser14Phe, Ser29Leu, Arg61Cys,
Cys88Arg, Gln97Lys, Pro117Leu, Ser189Leu, Arg206Cys,
Gly220Val, Thr245Met, Glu284Lys, Gly401Ser, Gly414Ala,Fig. 1 Schematic representation of the DNA samples and the genetic varia
analyses were performed using the enriched HGDP-CEPH panel only and w
panel. In the analyses that required unambiguous identification of the ge
the global loss-of-function, and the population genetic analyses) only the
used together with the 53 populations of the enriched HGDP-CEPH pane
PRU-1 K, CEU-1 K, and ASW-1 K were omitted in these analyses. b A flow
that were analyzed in detail in this study. The 21 variants were selected f
variants previously suggested in the literature to cause loss of OCT1 funct
diagram can be placed between the steps of ‘NextGen sequencing’ and
synonymous, and the predicted non-deleterious variants is available in A
they were previously reported to cause a more than 50 % decrease in O
be deleterious by at least five of eight software prediction packages use
prediction results are given in the text and in Additional files 3 and 6. The v
the enriched HGDP-CEPH panel, but were included in the detailed analyses
the 1000 Genomes project (Gly220Val) and fulfilled the criteria for deleteriouMet420del, Ile449Thr, and Gly465Arg) were validated by
single-base primer-extension reactions (SNaPshot®, Life
Technologies). The genotypes of another five variants
(Phe160Leu, Pro341Leu, Arg342His, Met408Val, and
Arg488Met) were validated by TaqMan®-based SNP geno-
typing assays (Life Technologies). Sex matching was per-
formed to exclude sample swaps and 5 % of the samples
were genotyped in duplicate, showing complete concord-
ance in the genotype calls. Arg488Met was genotyped both
by TaqMan® and single-base primer-extension. The two
methods showed 100 % concordance in the genotype calls.
The sequencing and genotyping methods are described in
details in the supplementary.
Construction and characterization of OCT1 overexpressing
cell lines
The OCT1-overexpressing HEK293 cells were generated
by targeted chromosomal integration using the Flp-In
SystemTM (Life Technologies, Darmstadt, Germany).
The construction and characterization of the cells over-
expressing OCT1 alleles *1 (wild type), *3, *4, *5, and *6nts that were analyzed in this study. a A flowchart illustrating which
hich using both the enriched HGDP-CEPH panel and the 1000 Genomes
ographical origin of the populations (the global frequency analyses,
nine non-admixed populations of the 1000 Genomes Project were
l. The highly admixed 1000 Genomes populations CLM-1 K, MXL-1 K,
chart illustrating the process of selection of the 21 genetic variants
rom the variants identified by high-throughput sequencing and the
ion. In the context of the analysis pipeline presented in panel a, this
‘Conventional genotyping’. A detailed list of the non-coding, the
dditional file 5. We regarded variants as potentially deleterious if
CT1 activity for at least one substrate; or if they were predicted to
d in this study. Details about the prediction software used and the
ariants Gln97Lys and Gly220Val were not identified by sequencing of
as they were previously reported in the literature (Gln97Lys, [17]) or in
s variants
Table 1 Worldwide distribution of OCT1 alleles
World region Population N chr. Major OCT1 alleles
*1 *2 *3 *4 *5 *6 *7 *8 *9 *10 *1 *12 *13 *14 *15 *16
Sub-Saharan
Africa
San 6 12 91.7 0 0 0 0 0 0 8.3 0 0 0 0 0 0 0 0
Mbuti
Pygmy
13 26 76.9 7.7 0 0 0 0 0 15.4 0 0 0 0 0 0 0 0
Biaka Pygmy 26 52 76.9 11.5 0 0 0 0 9.6 1.9 0 0 0 0 0 0 0 0
Bantu S.W. 8 16 87.5 6.3 0 0 0 0 6.3 0 0 0 0 0 0 0 0 0
Bantu N.E. 11 22 63.6 9.1 0 0 0 0 9.1 18.2 0 0 0 0 0 0 0 0
Bantu
(LWK-1 K)
97 194 88.1 4.1 0 0 0 0 2.6 5.1 0 0 0 0 0 0 0 0
Mandenka 22 44 90.9 4.6 0 0 0 0 2.3 2.3 0 0 0 0 0 0 0 0
Yoruba 22 44 95.5 0 0 0 0 0 2.3 2.3 0 0 0 0 0 0 0 0
Yoruba
(YRI-1 K)
88 176 90.3 2.3 0 0 0 0 1.7 5.7 0 0 0 0 0 0 0 0
Sub-Saharan
Africa mean
293 586 84.6 5.1 0 0 0 0 3.8 6.6 0 0 0 0 0 0 0




Mozabite 29 58 82.8 12.1 0 1.72 0 1.72 1.72 0 0 0 0 0 0 0 0 0
Bedouin 46 92 72.8 9.8 10.9 0 3.26 0 2.17 1.1 0 0 0 0 0 0 0 0
Palestinian 45 90 78.9 13.3 3.33 0 0 2.22 2.22 0 0 0 0 0 0 0 0 0




162 324 78.2 13.3 4.7 0.4 0.8 1.0 1.5 0.3 0 0 0 0 0 0 0 0
(range) (73.9-82.8) (9.8-17.9) (0.0-10.9) (0.0-1.7) (0.0-3.3) (0.0-2.2) (0.0-2.2) (0.0-1.12)
Europe Tuscan 8 16 87.5 12.5 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Tuscan
(TSI-1 K)
98 196 71.9 18.9 5.6 2.55 0.51 0 0 0.5 0 0.5 0 0 0 0 0 0
Sardinian 28 56 69.6 21.4 1.8 5.36 0 1.79 0 0 0 0 0 0 0 0 0 0
North Italian 14 28 89.3 7.14 3.6 0 0 0 0 0 0 0 0 0 0 0 0 0
Iberian
(IBS-1 K)
14 28 75.0 14.3 3.6 7.14 0 0 0 0 0 0 0 0 0 0 0 0
French
Basque
24 48 72.9 18.8 4.2 4.17 0 0 0 0 0 0 0 0 0 0 0 0
French 28 56 62.5 21.4 7.14 1.79 5.36 1.79 0 0 0 0 0 0 0 0 0 0
British
(GBR-1 K)
89 178 72.5 16.3 5.06 2.25 3.37 0.56 0 0 0 0 0 0 0 0 0 0
Orcadian 15 30 80.0 13.3 6.67 0 0 0 0 0 0 0 0 0 0 0 0 0













Table 1 Worldwide distribution of OCT1 alleles (Continued)
Finn
(FIN-1 K)
93 186 78.5 13.4 5.38 1.61 1.08 0 0 0 0 0 0 0 0 0 0 0
Adygei 17 34 70.6 17.6 5.88 0 2.94 0 0 0 0 2.94 0 0 0 0 0 0
Russian 25 50 66.0 10.0 10.0 6.00 8.00 0 0 0 0 0 0 0 0 0 0 0
Europe mean 570 1,140 74.4 15.5 5.1 2.5 1.8 0.3 0 0.04 0.3 0 0 0 0 0 0
(range) (62.5-89.3) (7.1-21.4) (0.0-10.0) (0.0-7.1) (0.0-8.0) (0.0-1.8) (0.0-0.5) (0.0-2.94)
Central Asia Balochi 24 48 66.7 27.1 6.25 0 0 0 0 4.2 0 0 0 0 0 0 0 0
Brahui 25 50 62.0 26.0 6.00 0 6 0 0 0 0 0 0 0 2 0 0 0
Makrani 25 50 84.0 16.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Sindhi 24 48 83.3 12.5 0 0 0 0 4.17 0 0 0 0 0 0 0 0 0
Pathan 25 50 72 26 2 0 0 0 0 0 0 0 0 0 0 0 0 0
Kalash 23 46 73.9 19.6 6.52 0 0 0 0 0 0 0 0 0 2.17 0 0 0
Burusho 25 50 84 6 6 0 4.00 0 0 0 0 0 0 0 0 0 0 0
Hazara 23 46 89.1 4.35 2.17 0 0 2.17 0 0 0 0 0 0 0 2.17 0 0
Uygur 10 20 80 15 5 0 0 0 0 0 0 0 0 0 0 0 0 0
Yakut 25 50 92.0 0 4.00 0 0 0 0 0 4.00 0 0 0 0 0 0 0
Central Asia
mean
229 458 78.7 14.8 3.8 0 1.0 0.2 0.4 0.42 0.4 0 0 0 0.4 0.2 0 0
(range) (62.0-92.0) (0.0-27.1) (0.0-6.5) (0.0-6.0) (0.0-2.2) (0.0-4.2) (0.0-4.2) (0.0-4.0) (0.0-2.2) (0.0-2.2)
East Asia and
Oceania
Dai 10 20 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
She 10 20 90.0 0 0 0 0 0 0 0 0 0 0 10.0 0 0 0 0
Tujia 10 20 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Yizu 10 20 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Naxi 9 18 94.4 0 0 0 0 0 0 0 0 0 5.56 0 0 0 0 0
Tu 10 20 90.0 0 0 0 0 0 0 0 0 0 0 0 0 0 5.0 0
Xibo 9 18 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mongola 10 20 85.0 10.0 0 0 0 0 0 0 5.00 0 0 0 0 0 0 0
Hezhen 9 18 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Daur 10 20 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Oroqen 9 18 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Han 45 90 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Han Beijing
(CHB-1 K)
97 194 98.5 0.52 0 0 0 0 0 0 0.52 0 0.52 0 0 0 0 0
Han South
(CHS-1 K)
100 200 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Lahu 8 16 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0













Table 1 Worldwide distribution of OCT1 alleles (Continued)
Cambodian 10 20 95.0 5.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Japanese 30 60 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Japanese
(JPT-1 K)
89 178 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Melanesian 14 28 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Papuan 17 34 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
East Asia and
Oceania mean
526 1,052 97.8 0.7 0 0 0 0 0 0 0.3 0 0.3 0.5 0 0 0.2 0.2
(range) (85.0-100.0) (0.0-10.0) (0.0-5.0) (0.0-5.6) (0.0-10.0) (0.0-5.0) (0.0-5.0)
America Colombian 7 14 57.1 42.9 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Karitiana 14 28 39.3 60.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Maya 21 42 66.7 33.3 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pima 14 28 82.1 17.9 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Surui 8 16 6.25 93.8 0 0 0 0 0 0 0 0 0 0 0 0 0 0






60 120 65.8 29.2 3.33 0.83 0.83 0 0 0 0 0 0 0 0 0 0 0
Mexican
(MXL-1 K)
66 132 59.1 32.6 4.55 0 3.03 0 0.76 0 0 0 0 0 0 0 0 0
Puerto Rican
(PUR-1 K)
55 110 76.4 20.0 0.91 0 1.82 0 0 0 0 0.91 0 0 0 0 0 0
Caucasians
(CEU-1 K)
85 170 72.4 15.3 8.82 1.76 1.18 0.59 0 0 0 0 0 0 0 0 0 0
Africans
(ASW-1 K)
61 122 87.7 8.20 1.64 0.82 0 0 0.82 0 0 0 0 0 0 0 0 0.82
Worldwide mean 2,171 4,342 81.0 12.2 2.14 0.57 0.65 0.16 0.68 0.99 0.14 0.07 0.09 0.15 0.07 0.03 0.07 0.01
(range) (6.3-100.0) (0.0-93.8) (0.0-10.9) (0.0-7.1) (0.0-8.0) (0.0-2.2) (0.0-9.6) (0.0-18.2) (0.0-5.0) (0.0-2.9) (0.0-5.6) (0.0-10.0) (0.0- 2.2) (0.2-2.2) (0.0-5.0) (0.0-0.6)
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alleles in the supplementary (Additional files 1 and 2).
OCT1 activity assays
The OCT1-mediated uptake was measured essentially as
described before [3, 4, 25]. The OCT1-mediated uptake
of tropisetron, debrisoquine, O-desmethyltramadol, and
monocrotaline was measured using HPLC, of ASP+
using fluorescence spectroscopy and of radiolabelled
MPP+, TEA+, morphine, metformin, and tyramine using
scintillation counting. The procedures are described in
details in the supplementary (Additional file 1).
Immunofluorescence confocal microscopy and western
blot analysis
The cells were trypsinized with 3.5 mL TryplLETM
Express (Life Technologies) for 4 min at 37 °C and
passed through a 40 μm strainer (BD Falcon, Heidelberg,
Germany). Two hundred thousand cells were seeded per
well of four-well chamber slides (Lab-Tek™ II, Nunc,
Wiesbaden, Germany), which were pre-coated with poly
D-lysine. The next day the cells were washed with phos-
phate buffered saline (PBS), fixed for 20 min with 4 %
formaldehyde, washed twice with PBS, and perme-
abilized for 15 min in blocking buffer (0.5 % fetal calf
serum (FCS), 0.1 % bovine serum albumin (BSA), and
0.05 % Triton X-100 in PBS). The cells were incubated
with the primary antibodies diluted in blocking buffer.
For primary antibodies we used mouse monoclonal anti-
OCT1 (2C5; Novus Biologicals, Cambridge, UK) diluted
1:400, rabbit monoclonal anti-Na+/K+ ATPase (EP1845Y)
diluted 1:200, or rabbit polyclonal anti-Calnexin (ab22595;
both obtained from Abcam, Cambridge, UK) diluted
1:1000. After 1 h incubation at room temperature, the
cells were washed three times for 5 min with blocking buf-
fer and incubated with the secondary antibodies for 1 h in
blocking buffer supplemented with 2.5 pg/mL DAPI (Life
Technologies). The incubation was performed at room
temperature with samples protected from direct light. As
secondary antibodies we used Alexa Fluor® 488 goat
anti-mouse or Alexa Fluor® 546 goat anti-rabbit IgG
diluted 1:500 (A-11001 and A11010, respectively; Life
Technologies). The cells were washed three times for
5 min with blocking buffer and once with PBS and
mounted with Fluoromount-G™ (Southern Biotech;
Birmingham, AL, USA). The samples were analyzed on
a laser scanning microscope (LSM 710; Carl-Zeiss,
Oberkochen, Germany) and the images were processed
using ImageJ software v. 1.47 (NIH, Bethesda, MD, USA)
with additional contrast adjustment for each channel.
The western blot was performed with total protein ex-
tracts of HEK293 cells stably transfected with the differ-
ent OCT1 variants. The detection was carried out using
mouse monoclonal anti-OCT1 (2C5; Novus Biologicals,Cambridge, UK) and monoclonal anti-GAPDH (6C5;
Zytomed, Berlin, Germany) as primary antibodies and
horseradish peroxidase-conjugated anti-mouse antibody
(BioMol, Hamburg, Germany) as secondary antibodies.
Procedure is described in detail in the supplementary.
Computational analyses
Individual OCT1 haplotypes were inferred using PHASE
version 2.1 [26]. Ten independent runs with different
seeds (2, 1,536, 2,936, 3,123, 4,957, 5,283, 6,757, 7,992,
8,633, 9,045) were performed to exclude seed-biased
assignments.
Effects of the non-synonymous variants in OCT1 on
protein function were predicted using eight different
tools: PROVEAN version1.1.3, SIFT version 1.0.3,
PolyPhen-2 version 2.2.2, MutPred version 1.2, Mutation
t@sting version 2, SNPs3D, SNAP, and PhD SNP (for
details see Additional file 3).
Analysis of molecular variance (AMOVA) was per-
formed on three levels, within population, among popu-
lations within each geographic region and among the
geographic regions. The calculations were done using
Arlequin v3.5.1.2 [27] for the 62 populations in six world
regions worldwide. The admix populations from the
1000 Genome Project were excluded from the analysis.
Data were entered as DNA sequence data (haplotypic)
as the input method for the 16 haplotypes, while we
used the allele frequency input method for the pheno-
types. Phenotypes were coded as 0, 1, and 2 referring to
zero, one, and two active OCT1 alleles, respectively.
The calculations of the average nucleotide diversity (π),
the estimation of the population mutation parameter (θ),
and the test for neutrality (Tajima’s D) were performed
using Arlequin v3.5.1.2 [27]. The values for π and θ were
normalized to the size of the coding region of the OCT1
gene. All parameters were calculated independently for
the six major world regions, and the nine admixed popula-
tion of the 1000 Genomes Project were excluded from the
analysis.
Results
Global genetic variability in OCT1
Applying semiconductor-based massively parallel se-
quencing, we analyzed the global genetic variability in
the coding regions of OCT1. We resequenced 2,770 bp
of the OCT1 gene, including the complete coding region,
the untranslated regions and the intron-exon junctions
(Additional file 4). We obtained more than 7.1 million
mapped sequencing reads. The average coverage depth
was 173-fold per sample (range 17 to 402) with 977 sam-
ples (91.3 %) having average coverage above 50-fold. The
complete sequencing dataset and individual genotypes
were deposited and are freely available in the HGDP-
CEPH Database [28].
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all variants is available in Additional file 5). Thereof 44
variants were within the coding region of OCT1 and 29
of them caused amino acid substitutions. We selected 21
amino acid substitution variants for our subsequent ana-
lyses (see Fig. 1b for the selection strategy). Included
were 14 amino acid substitutions that may affect OCT1
activity (Fig. 2a): nine variants previously known to
cause loss of OCT1 activity (Ser14Phe, Arg61Cys,
Cys88Arg, Pro117Leu, Ser189Leu, Arg206Cys, Gly401-
Ser, Met420-deletion, Gly465Arg) [2–5, 7, 10, 11, 17]
and five variants predicted to cause loss of OCT1 func-
tion (Ser29Leu, Thr245Met, Glu284Lys, Gly414Ala,
Ile449Thr). To predict loss of OCT1 function we used
eight independent prediction tools. Variants that were
predicted to be deleterious by at least five of the eight
prediction tools were regarded as potential loss-of-
function variants (Additional file 6). We also genotyped
two variants, Gln97Lys and Gly220Val, which were not
identified in our population by massively parallel se-
quencing. However, Gln97Lys was previously reported in
the literature to strongly affect OCT1 activity [17], while
Gly220Val was observed in the 1000 Genomes project
and was predicted to be deleterious (Additional file 6).
Furthermore, we analyzed five amino acid substitutions
(Leu160Phe, Pro341Leu, Arg342His, Met408Val, and
Arg488Met) that were known to either not affect or
to cause less than 50 % reduction in OCT1 activity
[2, 10, 11, 20, 21]. We included these variants for
two reasons. First, we wanted to obtain information
about the effects of these variants on the uptake of a
much broader spectrum of substrates than previously
tested. Second, we aimed to identify common amino
acid substitutions that do not affect OCT1 activity as
a control in our population genetic analyses.
The methionine420 deletion (Met420del) was the most
commonly observed loss-of-function variant among the
1,079 individuals from 53 populations analyzed (world-
wide minor allele frequency of 14.1 %). The other com-
mon loss of function variants were Arg61Cys (3.2 %),
Gly465Arg (1 %), Ser14Phe (0.8 %), and Gly401Ser
(0.7 %). The variants Ser29Leu, Cys88Arg, and Pro117-
Leu were observed only in two, eight, and four unrelated
individuals, respectively. The variants Ser189Leu,
Arg206Cys, Thr245Met, Glu284Lys, and Ile449Thr were
observed only in single individuals. The variant Gly220-
Val was observed in a single individual in the 1000
Genomes sample and was missing in the HGDP-CEPH
samples. The variant Gln97Lys was not observed in ei-
ther sample set.
Among the loss-of-function OCT1 variants, Met420-
del was the only ubiquitous OCT1 variant that was
observed on all continents (Fig. 2b). The Ser14Phe,
Arg342His, and Arg488Met variants were frequent inAfrica and occasionally observed in the Middle East and
Central Asia, but were completely missing in Europe
and America. In contrast, the variants Arg61Cys and
Gly465Arg were frequent in Europe, occasionally ob-
served in the Middle East and Central Asia, but com-
pletely missing in Africa and America. The rare variants
Ser29Leu, Pro117Leu, Arg206Cys, Thr245Met, Glu284Lys,
and Ile449Thr were observed only in Asians populations.
Among the variants that were not expected to strongly
affect OCT1 function, Met408Val was the most frequent.
Pro341Leu was the second-most frequent variant. It was
observed in all the world regions, but was more common
in East Asia.
Comparison with the primate OCT1 sequences
showed that, with the exception of serine14 and ar-
ginine488, all the major alleles in humans were also
the ancestral alleles (Additional file 7). The primates
have phenylalanine at codon 14 and methionine at
codon 488 while the major allele in humans is serine14
and arginine488, respectively.
OCT1 alleles and their functional characteristics
Using haplotype inferring of the extended HGDP-CEPH
and the 1000 Genome Project data we identified 30 hap-
lotypes (Fig. 3a). The haplotypes were grouped to 16
major alleles (designated *1 to *16) and 14 sub-alleles
(designated with a capital letter after the major allele
number, for example, *1A, *1B, and so on). As sub-
alleles we defined alleles that do not showed more than
50 % reduction or 50 % increase of the activity compared
to the corresponding major allele with any of the sub-
strates tested (for details see Fig. 4 and the text below).
The non-synonymous variants causing substantial changes
in OCT1 activity the variants Cys88Arg, Arg206Cys, and
Gly465Arg were not observed alone, but in combination
with the Met420del variant (Fig. 3b).
Whereas the allele structure was the same in all popu-
lations studied here, the frequencies of the alleles varied
substantially among the world regions. The global popu-
lation frequencies of the major OCT1 alleles are shown
in Table 1 and detailed information regarding the allele
frequencies of the sub-alleles is given in Additional file 8.
Next to the major OCT1*1 allele, OCT1*2 was the only
evolutionary old major allele observed in all populations.
OCT1*2 was the only loss-of-function allele that was ob-
served in Native Americans. Alleles *3 to *8 were region-
specific: *3 was observed in Europe, the Middle East and
Central Asia, *7 and *8 were observed in Africa, the
Middle East, and occasionally in Central Asia. Alleles *9 to
*16 were very rare on a global scale (allele frequencies of
below 0.5 %). However, in some specific populations their
frequencies may be much higher, for example, the
OCT1*12 allele frequency reached 10 % in the population
of She Chinese (Table 1).
Fig. 2 Non-synonymous OCT1 polymorphisms causing potentially functional amino acid substitutions, and their distribution in different world
regions. a The localization of the 21 polymorphisms analyzed in details in this study. Substitutions previously reported in the literature to have
strong functional effects on OCT1 activity are shown in black (reported loss of function), substitutions predicted to affect OCT1 activity are shown
in gray (predicted loss-of-function), and substitutions previously reported to not affect or to cause less than 50 % reduction of OCT1 activity are
shown in white (reported to lack strong effects). The polymorphisms are designated with the amino acid substitutions that they cause and the
codon that is affected. Their rs-number in the dbSNP database (if available) and their location on chromosome 6 according to the human genome
assembly hg19 are also given. b Minor allele frequencies of the 16 known or predicted loss-of-function OCT1 polymorphisms. Shown
are 39 populations from Sub-Saharan Africa, North Africa and the Middle East, Central Asia, Europe, and America. The 39 populations
shown include 35 populations from the CEPH human genome diversity panel and five from the 1000 Genome Project [24] (designated
with 1 K). The populations CEU, ASW, MXL, PUR, and CLM from the 1000 Genomes Project were omitted from these analyses due to
their highly admixed structure and/or inability to be allocated to a defined world region
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Fig. 3 OCT1 alleles and their global distribution. a Shown are the haplotype combinations constituting the 16 major and 14 sub-alleles of OCT1
observed in the worldwide genetic analyses. As major we defined alleles carrying amino acid substitutions (highlighted in yellow) that cause a
more than 50 % decrease or 50 % increase of OCT1 activity in comparison to the reference OCT1*1 allele for at least one substrate tested. The
sub-allele of a major allele differs by amino acid substitutions (highlighted in white) that do not affect OCT1 activity. For details about variants
affecting or not affecting OCT1 activity see Fig. 4 and the results section in the text. b Cladogram illustrating the relations between the major
OCT1 alleles and their worldwide distribution. Different world regions are indicated in colors. Pie size represents the global allele frequency.
The amino acid substitutions that distinguish between the alleles are shown. Allele OCT1*16 is missing from the cladogram as it was observed
only in admixed population from the 1000 Genomes Project and could not be assigned to any world region. The cladogram was generated
using the median joining algorithm of the NETWORK software version 4.6 (Fluxus Technology Ltd.)
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non-synonymous variants. Two non-synonymous vari-
ants, Gln97Lys and Gly220Val, were omitted from the
analyses. Gln97Lys was not observed in any of the sam-
ples studied here. Gly220Val was observed only in a
single individual from an admixed population that could
not be used in the global loss of OCT1 functionanalyses. The 19 variants tested constituted 22 alleles:
the 15 major alleles and the seven most common sub-
alleles. The 22 alleles tested represent a total of 4,321 of
the 4,342 chromosome 6 copies of the individuals ana-
lyzed in this study (Fig. 3a). We characterized the func-
tional activity of the OCT1 alleles in stably transfected
HEK293 cells. The transfection resulted in a strong and
Fig. 4 Comparative analyses of the activity of the different OCT1 alleles using 10 different OCT1 substrates. Shown are the effects of the major
OCT1 alleles (a) and the six most common sub-alleles (b). The allele activity was determined with cellular uptake measurements in HEK293 cells
overexpressing different OCT1 alleles. The uptake was measured after incubation for 2 min with 10 μM MPP+, 5 μM TEA+, 5 μM ASP+, 1 μM
morphine, 5 μM metformin, 10 μM tyramine, or 1 μM monocrotaline, incubation for 1 min with 1 μM debrisoquine or 1 μM O-desmethyltramadol,
or for 3 min with 1 μM tropisetron. OCT1-mediated uptake was calculated by subtracting the uptake in HEK293 cells transfected with the empty
pcDNA5/FRT vector from the uptake in the cells transfected with the different OCT1 alleles. The results were represented as a percent of the uptake
in the cells transfected with the OCT1*1 allele (shown in black). The values for the uptake of morphine and tropisetron by alleles *3, *4, *5, and *6
are from our previously published studies [3] and [5], respectively. The comparison between OCT1*7A and OCT1*7B alleles (b) were made
after transient transfection. All the remaining experiments were performed after stable transfection in HEK293 cells. Shown are mean and
standard error of the means of three or more independent experiments
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OCT1 alleles (Additional file 2). We measured the ability of
the isoforms encoded by the different alleles to transport
the model OCT1 substrates 1-methyl-4-phenylpyridinium
(MPP+), tetraethylammonium (TEA+), and 4-(4-(dimethyla-
mino)styrl)-N-methyl-pyridinium (ASP+), the drugs debri-
soquine, morphine, metformin, tropisetron and O-
desmethyltramadol (the active metabolite of tramadol), and
the naturally occurring substances tyramine and monocro-
taline (Fig. 4a). Tyramine is a biogenic amine suggested to
be an OCT1 substrate [29] and was transported by
OCT1*1 in our hands with a KM of 94.7 μM and VMAX
of 381 pmol/mg protein/min (Additional file 9).
The overexpression of wild-type OCT1 (OCT1*1)
resulted in an increase in the uptake of the sub-
stances tested by at least 1.9-fold (range 1.9- to 24.1-fold,Additional file 10). The non-synonymous variants
Phe160Leu, Pro341Leu, Arg342His, Met408Val, and
Gly414Ala did not cause a more than 50 % decrease
or 50 % increase in OCT1 activity with any of the
substrates tested (Fig. 4b). Therefore haplotypes car-
rying these variants were designated as sub-alleles
(Fig. 3).
In addition to the sub-alleles, which did not show
strong changes to the OCT1*1 activity, we identified
two gain-of-function OCT1 alleles (the major alleles
OCT1*8 and OCT1*9) and 11 loss-of-function alleles
(the major alleles OCT1*2 to *7 and OCT1*10 to *15;
Fig. 4a). The allele OCT1*8 (characterized by the pres-
ence of the Arg488Met substitution) showed a more
than 50 % increase in the uptake of TEA+, morphine,
metformin, and monocrotaline. The allele OCT1*9
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morphine.
The major alleles showing loss of activity could be also
separated in three independent groups. The alleles *5 (a
combination of Gly465Arg and Met420del), *6 (a com-
bination of Cys88Arg and Met420del), *12 (Ser29Leu),
and *15 (Glu284Lys) showed complete loss of OCT1
activity independent of the substrate used (Fig. 4). The
alleles *3 (Arg61Cys), *4 (Gly401Ser), and *14 (a combin-
ation of Arg206Cys and Met420del) showed strong, but
not complete, loss of activity also independent of the
substrate. In contrast, the alleles *2 (Met420del), *7
(Ser14Phe), *10 (Ser189Leu), *11 (Ile449Thr), and *13
(Thr245Met) showed substrate-specific loss of activity.
The transport activity of alleles *2, *7, *10, and *11 was
reduced to 0 % of the OCT1*1 activity with some of the
substrates tested, but was more than 90 % for others
(Fig. 4a).
We analyzed the combined effects of the Met420del
and Met408Val variants on OCT1 activity in terms of
affecting subcellular localization and activity of OCT1.
Neither the presence of the Met420 deletion, nor
Met408Val affected the correct localization of OCT1 at
the plasma membrane (Additional file 11). The presence
of Met420del resulted in a substrate-specific loss of
OCT1 activity. The Met408Val substitution did not
cause differences in the transport of metformin, tyram-
ine, or debrisoquine. However, a small but significant
increase of morphine uptake was observed when me-
thionine408 was substituted to valine suggesting that
when morphine is used as a substrate OCT1*2 allele
should be regarded as a reduced activity allele (and
not as a complete loss of activity allele as suggested
earlier [3]).
We analyzed the ability of model substrates to predict
the ability of the alleles that conferred substrate-specific
loss of OCT1 activity (*2, *7, *10, *11, and *13) to trans-
port the clinically relevant drugs metformin and mor-
phine (Additional file 12). There was no single model
substrate that was able to accurately predict the effect of
OCT1 variants on the uptake of both drugs. Whereas
morphine uptake correlated better with ASP+ uptake,
metformin uptake correlated better with TEA+ uptake.
These results underline the substrate-specific effects of
variants *2, *7, *10, *11, and *13 with the consequence
that there will not be a single model substrate com-
pletely reflecting the effects of these genetic variants on
OCT1 activity.
Next we analyzed the subcellular localization of the
OCT1 isoforms encoded by the 14 major alleles and the
four most common sub-alleles. Most isoforms with
substrate-wide loss of function failed to localize in the
plasma membrane (Fig. 5a). Co-localization with cal-
nexin suggested retention in the endoplasmic reticulum.Therefore, lack of correct localization was the major rea-
son for substrate-wide loss of OCT1 activity. The only
exception was the allele OCT1*4 (Gly401Ser). OCT1*4
was correctly localized in the plasma membrane, but
had between 0 and 28 % of the wild type activity in the
substrates tested (Fig. 4a). In contrast, the isoforms with
substrate-dependent loss of activity showed normal cel-
lular localization (Additional file 13).
The lack of plasma membrane localization correlated
with an altered glycosylation pattern of OCT1 (Fig. 5b).
Western blot analyses showed that the variants that
were not properly localized in the plasma membrane
(OCT1*5, *6, *12, *15, and partially *3 and *14)
lacked their PNGaseF-sensitive and EndoH-resistant
glycosylation, but kept their EndoH-sensitive glycosylation.
Global variations in loss of OCT1 activity
Finally and most importantly, we analyzed the frequency
of genotypically predicted loss of OCT1 activity world-
wide. To this end we categorized the individuals as car-
riers of two, one or zero completely active OCT1 alleles.
We regarded the OCT1 alleles *1, *8, and *9 as com-
pletely active. The remaining major alleles *2, *3, *4, *5,
*6, *7, *10, *11, *12, *13, *14, and *15 we regarded as
loss of activity as they show more than 65 % reduc-
tion in the OCT1 activity with at least one substrate
tested (Fig. 4a).
Between Europeans there were only minor differences
in frequency of loss of OCT1 activity (Additional file 14).
On average 53 % of the Europeans carried two, 38 % one
and 8 % zero active OCT1 alleles. These values were
similar to those reported before [4, 10, 11]. A slightly
higher frequency of loss of OCT1 activity was observed
in Russia and a slightly lower frequency in Northern Italy,
but this may be due to the small size of the population
samples (25 and 14 individuals, respectively).
Worldwide, we observed strong variations in the fre-
quency of loss of OCT1 activity (Fig. 6). Whereas all indi-
viduals from Japan and Oceania carried two completely
active OCT1 alleles, the majority of the Surui Indians car-
ried two completely inactive OCT1 alleles. Out of eight
Surui Indians analyzed, one (13 %) carried only one and
the remaining seven (87 %) completely lacked any active
OCT1 alleles. Similarly to the individuals from Japan, more
than 98 % of the Han Chinese, the major population in
China, carried two completely active OCT1 alleles and the
remaining less than 2 % carried one (Additional file 14).
Similar to the Surui, other South American Indians had
high frequencies of loss of OCT1 activity, for example, only
7 % of the Karitina Indians carried two completely active
OCT1 alleles, 64 % carried one, and 29 % lacked any com-
pletely active OCT1 alleles.
Analyses of molecular variance (AMOVA) showed
strong variability among the regions of the world at
Fig. 5 Subcellular localization and glycosylation patterns of the isoforms encoded by the major OCT1 alleles. a The subcellular localization of the
OCT1 isoforms showing that the major cause for substrate-wide loss of OCT1 activity is improper subcellular localization. Shown are the
OCT1-overexpressing HEK293 cells stably transfected with alleles causing substrate-wide loss of OCT1 function, and the HEK293 cells expressing the
wild type (OCT1*1) as a reference. The subcellular localization was analyzed with confocal microscopy after immunocytochemical staining for OCT1
(green). The exact OCT1 localization was analyzed using co-staining with Na+/K+ ATPase (red, upper part) as a marker for the plasma membrane
and calnexin (red, lower part) as a marker for the endoplasmic reticulum. The immunocytochemical analyses of the sub-alleles and the alleles
causing gain or substrate-specific loss of OCT1 function are shown in Additional file 13. b Western blot analyses of total cellular protein illustrating
differences between the glycosylation patterns of OCT1 isoforms correctly localized in the plasma membrane and those retained in the endoplasmic
reticulum. OCT1 was detected as a double signal of a close to 70 kDa large PNGaseF-sensitive and EndoH-resistant glycosylation form and a 50 kDa
EndoH-sensitive glycosylation form. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control
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(10.5 % and 18.7 %, respectively; Table 2). Within the
different geographic regions the highest variability among
the populations was observed by the Native Americans(36.3 % at phenotypic level) compared to only 1.3 % by
the European populations.
Pairwise FST values analyses showed strong divergence
in the loss of OCT1 activity between the America and
Fig. 6 World map of genetically determined loss of OCT1 activity. Frequencies of carriers of two (green), one (orange), and zero (red) completely
active OCT1 alleles are shown for different regions around the world. The major alleles OCT1*1, *8, and *9 were regarded as completely active
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results were obtained by analyzing the OCT1 genetic
variability at the genetic level without regarding the
functional effects of the haplotypes (FST of 0.72,
Additional file 15). There was only limited positive
correlation between the frequency of loss of OCT1
activity and the geographic distance to Addis Ababa,
which may be regarded as a starting migration point of
the modern humans according to the Out-of-Africa










World 1 62 89.2 10.8
World 6 62 87.4 2.1
Sub-Saharan Africa 1 9 97.6 2.4
North Africa and
Middle East
1 4 99.9 0.1
Europe 1 13 100.0 0.0
Central Asia 1 10 96.2 3.8
East Asia and Oceania 1 21 94.9 5.1
America 1 5 75.6 24.4was much stronger when the populations from East Asia
and Oceania were excluded from the analyses (r2 = 0.640,
P <10−4, Fig. 7c).
In addition, we took advantage of the available geno-
types of the HGDP-CEPH individuals for another poly-
morphic drug transporter OATP1B1 [30] and the
metabolizing enzyme CYP2D6 [31] and analyzed the
correlation between loss of OCT1 activity and loss of
OATP1B1 or CYP2D6 activity. We regarded the pres-
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Fig. 7 Analyses of the variations in the frequencies of loss of OCT1 activity. a Pairwise comparison of the divergences between the populations
and between the world regions (the upper panel). The divergences between the populations were shown in terms of pairwise fixation indexes
(FST). The deep blue color corresponds to high divergence between the populations / regions (high FST values). We analyzed 62 populations from
the 1000 Genomes Project (designated with 1 K) and HGDP-CEPH project (the rest). The populations were stratified in world regions as shown in
Table 1. The populations CEU, ASW, MXL, PUR, and CLM from the 1000 Genomes Project were omitted from these analyses due to their highly
admixed structure and/or inability to be allocated to a defined world region. b and c Correlation analyses between the loss of OCT1 and
geographic distance to Addis Ababa. Shown are all HGDP-CEPH populations (b) and populations outside East Asia and Oceania (c). The
distances to Addis Ababa are according to the previously published ones [37]. Shown are Pearson’s correlation coefficients. The number
of populations analyzed were 50 in (b) and 32 in (c). d and e Correlation analyses between the loss of OCT1 and of OATP1B1 activity in
HGDP-CEPH populations. Shown are all populations (d) and populations outside Asia and Oceania (e). Loss of OATP1B1 activity is represented as
the presence of the C-allele of the c. 521 T > C polymorphism. The carrier of the C-allele were estimated from the population data of Pasanen et al.
[30] assuming Hardy-Weinberg distribution of the genotypes within each population. Shown are Pearson’s correlation coefficients. The number of
populations analyzed were 52 and 24 in (d) (e), respectively
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in vivo to be the common polymorphism that most
strongly affects OATP1B1 activity [32–34]. The fre-
quency of loss of OCT1 activity correlated with the fre-
quency of loss of OATP1B1 activity (r = 0.531, P <10−4,
Fig. 7d). The correlation was much stronger when the
Asian and Oceanian populations were excluded from the
analyses (r2 = 0.789, P <10−5, Fig. 7e). We regarded the
presence of any of the nonfunctional CYP2D6 alleles,
CYP2D6 *3, *4, *5, or *6, as a loss of CYP2D6 activity.
No correlation was observed between the loss of OCT1
activity and loss of CYP2D6 activity (data not shown).
Next we performed classical population genetic ana-
lyses to test for neutrality of the observed loss of OCT1
function. We analyzed the region-specific variation in
nucleotide diversities (π) of the amino acid substitutions
in OCT1 and compared them with the expected average
heterozygosity (also known as population mutation par-
ameter θ; Table 3). The observed nucleotide diversity in
the different world regions was on average 5.88 × 10−4,
which was very close to the previously reported value
(5.11 × 10−4, [16, 35]). The nucleotide diversity varied be-
tween 3.6 × 10−4 and 7.9 × 10−4 among the world regions
(Table 3).Table 3 Population genetic statistics of the OCT1 gene for the diffe
World region π (×10−4)
All LOF Non-LOF πLOF / πnon-LOF
Sub-Saharan Africa 4.91 0.85 4.06 0.21
North Africa and Middle East 5.73 2.59 3.15 0.82
Europe 7.93 3.06 4.87 0.63
Central Asia 7.60 2.36 5.24 0.45
East Asia and Oceania 5.48 0.16 5.32 0.03
America 3.63 2.76 0.87 3.18
LOF, loss-of-function. Included are all variants causing a more than 50 % reduction
Arg61Cys, Cys88Arg, Ser189Leu, Arg206Cys, Thr245Met, Glu284Lys, Gly401Ser, Met4
variants that did not affect or caused an increase in OCT1 activity, that is, Pro117Le
*P <0.01We took advantage of the detailed functional analyses
that we performed in this study and analyzed separately
the nucleotide diversity for the amino acid substitutions
causing loss of OCT1 function (πLOF) and the ones not
causing loss of function (πnon-LOF). We observed strong,
more than 10-fold variations in πLOF among the different
world regions (Table 3). By far the lowest πLOF was ob-
served in East Asia and Oceania (0.16 × 10−4). In
addition, the ratio of πLOF to πnon-LOF was extremely low
for East Asia and Oceania (0.03 compared to an average
of 0.89 for the whole world regions, Table 3). Further-
more, the observed loss-of-function nucleotide diversity
in East Asia and Oceania was significantly lower than
the expected value (θ of 4.8 × 10−4; Tajima’s D of −1.64,
P <0.01). This indicates the presence of purifying selec-
tion for loss-of-function OCT1 variants in this region. In
contrast, the ratio of πLOF to πnon-LOF variants in Native
Americans was very high, but the difference between the
observed and expected loss-of-function nucleotide diver-
sity was not significant (Table 3).
Discussion
The comprehensive population and functional genetic
analyses performed in this study revealed strongrent world regions
θ (×10−4) Tajima’s D
All LOF Non-LOF All LOF Non-LOF
5.19 1.73 3.46 −0.096 −0.601 0.271
9.45 5.67 3.78 −0.869 −1.040 −0.280
8.52 4.65 3.87 −0.140 −0.568 0.400
11.73 5.42 6.32 −0.803 −1.042 −0.330
7.99 4.79 3.20 −0.621 −1.638* 0.976
4.25 1.06 3.18 −0.268 1.675 −1.204
in OCT1 activity for at least one substrate tested, that is, Ser14Phe, Ser29Leu,
20del, Ile449Thr, and Gly465Arg; non-LOF, non-loss-of-function. Included are all
u, Phe160Leu, Pro341Leu, Arg342His, Met408Val, Gly414Ala, and Arg488Met
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loss of OCT1 activity among populations around the
world. Whereas in East Asia lack of OCT1 activity was
very rare, lack of OCT1 activity was very common in
some native South American populations, who were
mostly carriers of the OCT1*2 allele. Depending on the
substrate, more than 80 % of the Surui Indians completely
lack OCT1 activity and the remaining less than 20 % have
only one active OCT1 allele. The genetic variability of
OCT1 among different world regions was much higher
compared to other genes involved in the detoxification of
xenobiotics and known for their high genetic variability
like CYP2D6. Whereas a previously published analysis of
genetic variability of CYP2D6 in the HGDP-CEPH panel
found only 6.5 % phenotypic variability among world
regions [31], here we observed 18.7 % variability for
OCT1 (Table 2).
The observed strong population-specific loss of OCT1
activity may reflect in population-specific differences of
pharmacokinetics and therapeutic efficacy of some
commonly used drugs. Thus far, most clinical studies
on OCT1 polymorphisms have been performed in
Caucasians. Using the data from this study, the re-
sults may be extrapolated to other populations
worldwide. Numerous drugs including metformin,
morphine, tramadol, and tropisetron have been sug-
gested to depend on OCT1 transport to be metabo-
lized or to exert their pharmacological effects [2–5].
Furthermore, genetically determined loss of OCT1 activ-
ity was found to correlate with variations in the pharma-
cokinetics and the efficacy of these drugs [2–5, 12]. Based
on the results of this study it should be expected that
populations from East Asia and Africa will have gener-
ally lower and less inter-individually variable plasma
concentrations of these drugs. Indeed, Sadhasivam et
al. reported lower plasma concentrations of morphine
in the children of African Americans, compared to
white Americans [36] and suggested that this may be
due to the more common loss of OCT1 activity in Cau-
casians compared with Africans [12]. This hypothesis is
supported by our data. Our analyses showed that in
Sub-Saharan Africa only 5 % of the population carry al-
leles causing a reduction in OCT1-mediated uptake of
morphine, in contrast to 25 % in Europe (Table 1 and
Fig. 4a).
The highly variable frequency of loss-of-function
OCT1 polymorphisms suggests the existence of selec-
tion pressure for losing (or maintaining) OCT1 activity
in some world regions. The strongest divergence in the
frequency of losing OCT1 activity was observed between
the populations in America and East Asia (Fig. 7a).
Native Americans and East Asians, however, shared a
recent common ancestor and have low genetic diver-
gence on a genome-wide scale [37]. This suggeststhat a selection pressure exists either for maintaining
OCT1 activity in East Asia or losing OCT1 activity
in America.
Several population genetic analyses pointed to a
pressure for maintaining OCT1 activity in East Asia
and Oceania. First, and most important, the observed
loss-of-function variability in East Asia and Oceania
was significantly lower than the expected one (Tajima’s
D = −1.64, P <0.01; Table 3). In addition, the ratio of the
loss-of-function and the non-loss-of-function amino acid
substitutions was more than 10-fold lower in East Asia
and Oceania than in the other world regions. Second, we
observed a correlation of moderate significance between
loss of OCT1 activity and population migration distance
(Fig. 7b). This correlation was strongly improved when
East Asian populations were excluded from the analyses
(Fig. 7c). In addition, significant correlation was observed
between the frequencies of loss of activity of OCT1 and
OATP1B1, another genetically variable drug transporter
expressed in the liver (Fig. 7d) [30]. This correlation
was again substantially improved when East Asian and
Oceania populations were excluded from the analyses
(Fig. 7e). Taken together these data suggest that a se-
lection pressure for maintaining OCT1 activity in East
Asia may be the major cause for the strong divergence
in OCT1 activity between East Asia and America.
Finding the cause of this pressure may shed a light on
the important question about the physiological role of
OCT1 in humans.
In other polymorphic genes responsible for drug me-
tabolism and disposition, toxins have been suggested as
an important source of selection pressure [38]. In the
case of OCT1 selective pressure may come from food-
derived organic cations or hydrophilic weak organic
bases that are toxic if not rapidly detoxified in the liver.
Although the truly responsible component remains
unknown, we may illustrate the idea on the examples of
tyramine and monocrotaline.
Tyramine is a biogenic amine that is produced by
incomplete fermentation from bacteria like Carnobacter-
ium sp. and Lactobacillus sp. [39]. Substantial amounts
of tyramine and other biogenic amines are found in nu-
merous types of bacterially fermented foods (cheese,
some meat products, and red wine) [40]. Tyramine is de-
toxified by monoamine oxidases (MAO), which are
strongly expressed in the human liver [41]. Failure to de-
toxify tyramine can result in increased blood pressure,
migraine and nausea. Tyramine is a substrate of the hu-
man OCT1 ([29] and this work) and the alleles confer-
ring loss of OCT1 activity are not able to transport
tyramine (Fig. 4a). Therefore carriers of one and espe-
cially of zero active OCT1 alleles may experience in-
creased plasma concentrations and suffer from adverse
effects of tyramine. However, tyramine would execute a
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the high frequencies of loss of OCT1 activity.
A selection pressure for the loss of OCT1 activity may
exist for example if loss of OCT1 activity protects the
liver from toxic organic cations. An interesting example
is the case of monocrotaline, a pyrrolizidine alkaloid
which derives from the Crotalaria genus of flowering
plants. Monocrotaline may be ingested as a result of
contamination of food or beverages [42]. It undergoes
hepatic biotransformation into severely hepatotoxic
products [43], in an OCT1-dependent manner [9]. How-
ever, common OCT1 polymorphisms result in lack of
monocrotaline transport (Fig. 4a) and would thus pro-
tect the host against this toxicity. Although the global
distribution of Crotalaria sp. that produce these types of
toxins [44] does not overlap with the distribution of the
loss of OCT1 activity, this substrate is proof of principle
that lack of OCT1 activity could protect against ingested
toxins. Furthermore, several other hepatotoxic alkaloids
were recently reported to be OCT1 substrates [45, 46].
Alternatively, Oct1 deficiency in mice was reported to
protect from hepatic steatosis [1] and therefore may
improve fitness. However, it remains open to what ex-
tent the same effects are present in humans and it re-
mains elusive why Native Americans would be at a
higher risk of hepatic steatosis then populations in other
word regions.
Alternatively, the variable frequencies of loss of OCT1
activity may result from genetic drift processes like
founder effects and populations bottlenecks. This may
be especially true for the high frequency of loss of
OCT1 activity in Surui Indians. First, the South Ameri-
can Indians have traveled the longest migration distance
among the Homo sapiens populations and experienced
multiple founder effects [47]. This explanation is sup-
ported by the observed gradual increase in the frequency
of loss of OCT1 activity from North to South America
(Fig. 6). Second, Surui Indians have experienced a
population bottleneck about 45 years ago when more
than two-thirds of the Surui population died due to
diseases introduced by the first settlers [48]. This can
also explain the higher levels of the observed vs. ex-
pected nucleotide diversity in Native Americans (Tajima’s
D = 1.67; Table 3).
The average non-synonymous heterozygosity in OCT1
observed in this study (Table 3) was comparable with
previous reports [16, 35]. In the context of the other
organic cation transporters of the SLC22 family, the
average non-synonymous heterozygosity of OCT1 is
comparable with that of OCTN1 and substantially higher
than those of OCT2, OCT3, and OCTN2 [16, 35]. In the
context of the broader group of pharmacologically-
relevant membrane transporters, the average non-
synonymous heterozygosity of OCT1 is lower than thevalues for VMAT1, CNT1, and PEPT2, but is substantially
higher than the values of the dopamine and serotonin re-
uptake transporters DAT and SERT [16]. However, simple
comparisons between synonymous and non-synonymous
variability have the limitation that the non-synonymous
variants are automatically assumed to affect protein func-
tion. Here, after performing very broad substrate ana-
lyses, we found that five of the non-synonymous variants
(26 % of the functionally tested variants) do not substan-
tially affect OCT1 function. These variants were also
among the most frequent ones, with substantial contribu-
tion to the average heterozygosity. Of the remaining
variants, 12 (63 %) caused a decrease and another two
caused an increase in OCT1 function. Therefore, a
broader substrate-wide functional analysis of the non-
synonymous polymorphisms, similar to the analyses pre-
sented here for OCT1, may be more useful for addressing
the differences between functional and non-functional
variability in order to get more precise information on
neutrality.
One limitation of our study is the small number of in-
dividuals analyzed in some populations. For example,
the observed extremely high percentage of loss of OCT1
activity in Surui Indians is based on the analysis of only
eight individuals. However, even with this small number
of individuals, the probability that this observation has
been made by chance and that the frequency of loss of
OCT1 activity in Surui Indians is similar to the fre-
quency in Europe (the world region with the highest
frequency of loss of activity besides America) or in
Brahui individuals (the population with the highest
frequency of loss of activity outside of America) is
6.3 × 10−8 or 4.8 × 10−6, respectively. Still, with respect to
the particular case of the extremely high frequency of loss
of OCT1 activity in Surui Indians, we regard our data as
preliminary results that require validation.
Another important observation in our study is that the
major reason for substrate-wide loss of OCT1 activity is
improper membrane localization. With one exception
(Gly401Ser), all polymorphisms that caused complete
(Ser29Leu, Cys88Arg, Glu284Lys, Gly465Arg) or very
strong (Arg61Cys and Arg206Cys) substrate-wide loss of
OCT1 activity also cause retention of the protein in the
endoplasmic reticulum. This leads to lack or a strong re-
duction of protein expression at the plasma membrane
(Fig. 5). Several cysteine residues within the large extra-
cellular loop between transmembrane helices one and
two are involved in building intra-molecular disulfide
bonds essential for the oligomerization and for the
targeting of OCT1 to the plasma membrane [49]. In-
deed two polymorphisms causing improper membrane
localization, Cys88Arg and Arg61Cys, are located in the
large extracellular loop (Fig. 8a). Cys88Arg destroys a
cysteine residue known to build disulfide bonds [49] and
Fig. 8 (See legend on next page.)
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Fig. 8 Localization of the functional amino acid substitutions within the OCT1 protein. a Schematic representation of the secondary
structure of OCT1 with the positions of the amino acid substitutions causing strong changes in OCT1 activity indicated. Substitutions
leading to substrate-specific loss of activity are shown in orange, substitutions leading to partial, but substrate-overarching, loss of activity in red,
substitutions leading to complete substrate-overarching loss of activity in dark red, and substitutions leading to gain of function are shown in green.
The amino acids threonine516 and lysine 517, which are assumed to be involved in interaction with serine401 (see below), are shown in gray.
Potential phosphorylation (P) and glycosylation (ψ) sites are indicated as they were predicted by Zhang et al. [6]. b A 3D model of the OCT1
protein with the position of the Gly401Ser polymorphism highlighted. Represented is a homology model of the inward-facing conformation of
OCT1 (Model-ID Q9NQD4, ModBase [51]) which was visualized using PyMol software version 1.3 (Schrödinger, LLC, München, Germany). The
model is based on homology with lactose permease LacY of Escherichia coli (PDB number 1pv6). Gly401Ser substitution is shown as a red
sphere. Transmembrane helices TMH8, TMH9 and TMH12, the N terminus and C terminus are indicated. c A detailed representation of the region
of the Gly401Ser substitution indicating a potential hydrogen bond between the hydroxyl oxygen of serine401 and the carbonyl oxygen
of threonine516. A hydrogen bond could also be established between the hydroxyl oxygen of serine401 and the side chain amino group
of lysine517 assuming other rotational conformations for that side chains are allowed. The position of serine401, threonine516 and lysine517 are shown
in details. Oxygen atoms are depicted in red and nitrogen atoms in blue
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ect proximity to an already existing one.
Not all polymorphisms that affected the membrane
localization are located in the large extracellular loop.
Arg206Cys is located in the second extracellular loop
between transmembrane helices 3 and 4 (Fig. 8a), but it
also generates an extracellular cysteine (or facing the
endoplasmic reticulum during the protein synthesis).
This cysteine206 may interact with extracellular parts of
OCT1 or other molecules and act as an ‘anchor’ pre-
venting proper folding or translocation to the plasma
membrane. The other polymorphisms preventing the
OCT1 localization in the cell membrane are located ei-
ther in the first transmembrane domain (Ser29Leu) or in
the intracellular loops (Glu284Lys and Gly465Arg). The
Glu284Lys and Gly465Arg are changes in amino acids
that are highly conserved between species (orthologs)
and also between the members of the SLC22 family
(paralogs, see Additional file 7). The members of the
SLC22 family sharing this conservation recognize com-
pletely different substrates than OCT1 does. Therefore,
it could be speculated that these highly conserved
substrate-unspecific parts of the protein may have im-
portant structural functions and polymorphism affecting
them lead to improper structure of the protein and its
retention in the endoplasmic reticulum.
Gly401Ser apparently causes general impairment of
the transport process without affecting the membrane
localization of OCT1. Gly401Ser is located in the intra-
cellular loop between transmembrane helices 8 and 9
(Fig. 8a). Molecular modeling suggests that this loop is
in close proximity to the C-terminal end of transmem-
brane helix 12 and to the intracellular C-terminal tail of
the protein thereafter (Fig. 8b). When the structurally
flexible glycine401 is substituted with serine, a possible
interaction may occur between the hydroxyl group of
serine401 and the protein backbone between threonine516
and lysine517 (Fig. 8c). Accounting for the experimentally
observed substrate-wide loss of OCT1 activity, we mayspeculate that this interaction leads to impairment of a
general process like the protein plasticity essential for
the transmembrane translocation of the substrate.
A substantial number of the non-synonymous poly-
morphisms studied showed substrate-specific loss of
OCT1 activity. Five out of all 19 non-synonymous poly-
morphisms tested (26 %) and out of the 12 polymor-
phisms causing loss of OCT1 activity (42 %) showed
substrate-specific effects. This number is in line with the
analyses of Urban et al. who reported that 17 % of the
non-synonymous variants in drug transporters including
OCT1 show substrate-specific effects [35]. However, the
number given by Urban et al. may be an underestimate,
as it is based on the comparison of the effect of the poly-
morphism on only two substrates. Most polymorphisms
causing substrate-specific loss of OCT1 activity are lo-
cated in the transmembrane helices that are known to
be involved in the formation of the binding cleft (Fig. 8)
[50]. Although none of them affect amino acids known
to be involved in the substrate binding [50], they do
show up to 100 % reduction in the transport activity
with some substrates (Fig. 4). Substrate-specific effects
of the Met420del polymorphism (OCT1*2) have been re-
ported before. No differences were observed between
OCT1*2 and OCT1*1 in the uptake of MPP+ [11], but
strong differences were observed in the uptake of met-
formin, tropisetron or O-desmethyltramadol [2, 4, 5].
Substrate-specific differences were also observed for the
Ser14Phe and Arg61Cys polymorphisms when the up-
take of metformin and vitamin B1 (which behave fairly
similarly) was compared with the MPP+ uptake [1].
These substrate-specific effects were confirmed in the
present study making artifacts from the cloning strat-
egies or transport assays unlikely. Furthermore, our
data shows that the substrate-specific effects are more
general and are not restricted to the Met420del poly-
morphism and supports the existence of multiple
binding sites that strongly vary among different OCT1
substrates.
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high percentage of polymorphisms with substrate spe-
cific effects on OCT1 activity. It is not sufficient to test
the functional effects of a newly-identified amino acid
substitution using only one substrate; a variant active
with one substrate may be inactive with another sub-
strate. Thus, the concept of using model OCT1 sub-
strates especially for predicting effects of polymorphisms
on the transport activity should be critically re-
evaluated. Our experiments showed only limited and
strongly substrate-to-substrate variable ability of the
model OCT1 substrates MPP+, TEA+, and ASP+ to pre-
dict the effect of polymorphisms on the uptake of the
clinically relevant drugs (Additional file 12). Therefore,
at least until we do have more precise information about
the different substrate binding mechanisms of OCT1, the
effects of polymorphisms with known substrate-specific ef-
fects of OCT1 activity should be experimentally evaluated
for each new OCT1 substrate.
Conclusions
We observed strong inter-regional variations in the fre-
quency of loss of OCT1 activity. The differences in the
frequencies of loss of OCT1 activity should be taken in
consideration when transferring drug dosing recommen-
dations from one population to another. This strong
variability points the presence of an evolutionary selec-
tion for maintaining OCT1 activity in East Asian and
Oceania, but the selection agent remains unknown. The
major mechanistic cause of substrate-wide loss of OCT1
activity is improper membrane localization. However, a
substantial number of the variants showed substrate-
specific loss of activity. This reflects the poly-specificity
of the OCT1 transporter and suggests different substrate
binding sites and transport mechanisms for the different
OCT1 substrates.
Additional files
Additional file 1: Supplementary methods.
Additional file 2: Validation of HEK293 cells overexpressing different
OCT1 isoforms that were generated by targeted chromosomal
integration. (a) Schematic presentation of the expression plasmid pcDNA5.1
(black) integrated into the pFRT/lacZeo site of the chromosome of T-REx™
HEK293 cells (gray). The positions of the primers for validation PCRs are
indicated. (b) Results of the integration-specific amplifications (PCR 1)
and (PCR 2) validating the correct chromosomal integration of the
overexpressing constructs. The correctness of the PCR2 sequences was
validated by genotyping. (c) Quantitative real-time PCRs demonstrating
strong, and homogenous among the different isoforms, expression of
OCT1 in HEK293 cells.
Additional file 3: List of the different tools used for prediction of
the effects of OCT1 polymorphisms on protein function.
Additional file 4: Re-sequencing analyses of OCT1. (a) Size of the
re-sequenced regions stratified according their function: CDS, (protein)
coding sequence; UTR, untranslated region, and intron-exon borders.
(b) List of the 11 re-sequenced regions defined with their absolute andrelative positions at chromosome 6. (c) Schematic representation of the
targeted re-sequencing regions and an example of the sequencing
coverage. The amplicons from the two multiplex reactions used are
indicated in blue and red color. For details see the Materials and
methods section.
Additional file 5: A detailed list of genetic variants identified by
massively parallel sequencing of the enriched HGDP-CEPH samples.
Additional file 6: In silico prediction of functional impact of amino
acid substitutions observed in the worldwide genetic analyses of
OCT1.
Additional file 7: Evolutionary conservation of the variable OCT1
sites in OCT1 orthologs (upper part) and paralogs (lower part).
Additional file 8: A detailed worldwide distribution of OCT1 alleles
including the distribution of the sub-alleles.
Additional file 9: Characterization of tyramine uptake in HEK 293
cells overexpressing OCT1. (a) Tyramine inhibits the uptake of MPP+.
The cellular accumulation of 1-methyl-4-phenylpyridinium (MPP+) was
measured after 1 min exposure to 10 nM 3H MPP+ in cells overexpressing
OCT1*1. The graph shows mean values and standard errors of the mean
from three independent experiments. (b) Concentration dependence
of tyramine uptake. OCT1*1-overexpressing and control cells (stably
transfected with the empty pcDNA5.1/FRT plasmid were incubated for
1 min with increasing concentrations of tyramine. The graphs show mean
values and standard errors of the mean of three independent experiments.
(c) The OCT1-mediated uptake. The OCT1-mediated fraction of the total
uptake was calculated by subtracting the uptake in the control cells from
the uptake in OCT1*1-overexpressing cells using the dataset shown in (b).
Additional file 10: Differences in the uptake between OCT1*1
overexpressing (WT) and control cells stably transfected with the
empty pcDNA5.1/FRT plasmid (pcDNA5). The graphs show mean
values and standard errors of the mean of three or more independent
experiments.
Additional file 11: Lack of interaction between Met408Val and
Met420del polymorphisms in the OCT1 gene. (a) Comparison of the
uptake activity of OCT1 carrying all theoretically possible combinations of
the Met420del and Met408Val polymorphisms. The uptake was measured
in HEK293 cells stably transfected with the OCT1 variants or with an
empty control plasmid pcDNA5. Shown are means and standard error of
the means of at least three independent experiments. (b) Subcellular
localization of OCT1 isoforms carrying the four different combination of
the Met420del and Met408Val polymorphisms. The protein is located on
the plasma membrane indicated by co-staining with anti-Na+/K+ ATPase
as a plasma membrane marker. No qualitative differences could be
observed between cells carrying Met408 or Val408 independent from
their background (Met420 or Del420). (c) Frequencies of the different
single polymorphism genotypes (the upper part) and haplotype
combinations (the lower part) in the HGDP-CEPH sample. Individual
haplotypes were inferred using PHASE version 2.1. The genotype/
haplotype frequencies are given as number (and %) of all individuals.
Additional file 12: Correlation between the effects of substrate-
specific loss of function OCT1 alleles on the transport of model
substrates and clinically relevant drugs. We analyzed correlations
between the uptake of model OCT1 substrates (MPP+, TEA+, ASP+)
and clinically relevant drugs (metformin and morphine) for all the
OCT1 alleles that show substrate-specific loss of activity, that is, *2, *7,
*10, *11, and *13. Shown are means and standard error of the means
of at least three independent transport experiments. Solid lines represent
linear regression, dashed lines represent an optimal theoretical correlation
with identical effects of the loss-of-function allele on both the
model substrates and drug. * denotes significant correlations with
P <0.05.
Additional file 13: Correct subcellular localization of OCT1 alleles
*1, *2, *8, *9, *10, *11, and *13. The analyzed alleles are known to
have normal (OCT1*1, *1B, *1C, and *1D), increased (OCT1*8 and *9) or
substrate-specific loss of OCT1 activity (*2, *10, *11, and *13). The
subcellular localization of the different OCT1 isoforms was analyzed
after immunocytochemical staining of OCT1 (green) in combination
Seitz et al. Genome Medicine  (2015) 7:56 Page 22 of 23with Na+/K+ ATPase (red, upper part) as a marker for plasma membrane
and calnexin (red, lower part) as a marker for endoplasmic reticulum.
Additional file 14: Detailed maps of the interpopulation variation
of the frequency of loss of OCT1 activity in Europe (a) and China (b).
Additional file 15: Pairwise analyses of divergence based on the
frequencies of OCT1 alleles in populations and in different world
regions (the upper panel). The deep blue color correspond to high
divergence between the populations / regions (high FST values). We
analyzed 62 population from the 1000 Genomes Project (designated
with 1 K) and the HGDP-CEPH project (the rest). The populations were
stratified in world regions as listed in Table 1. In contrast to Fig. 7,
which shows divergence at the level of loss of OCT1 activity, this figure
shows divergences at the level of single OCT1 alleles.
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